CP
TNGX icon

Caligan Partners’s Tango Therapeutics TNGX Stock Holding History

Caligan Partners’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$50.4M Sell
2,408,798
-1,321,097
-35% -$18.4M 3.35% 9
2025
Q4 		$33M Buy
+3,729,895
New +$32.1M 2.72% 9

Other funds holding TNGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Caligan Partners's TNGX Position: Q1 2026 in Review

Caligan Partners reduced its Tango Therapeutics (TNGX) stake by 35% in Q1 2026, selling an estimated $18.4M and leaving 2,408,798 shares worth $50.4M. The position accounts for 3.35% of the portfolio, ranked #9.

Caligan Partners first reported a position in TNGX in Q4 2025 and has held it in 2 quarters since. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

  • Caligan Partners held 2,408,798 shares of Tango Therapeutics worth $50.4M as of Q1 2026.
  • Caligan Partners sold 1,321,097 Tango Therapeutics shares in Q1 2026, an estimated $18.4M.
  • Tango Therapeutics made up 3.35% of Caligan Partners's portfolio in Q1 2026, its #9 holding.
  • Caligan Partners first reported a position in Tango Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on Caligan Partners's 13F filing for Q1 2026, filed 15 May 2026.